stents

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and could eventually reduce the risk of coronary revascularization, especially complex revascularization.&nbsp; The FOURIER study randomized 27564 patients with stable CAD already on statins to evolocumab<a href="https://solaci.org/en/2020/11/25/aha-2020-effect-of-evolocumab-in-complex-coronary-revascularization/" title="Read more" >...</a>

AHA 2020 | El clopidogrel resiste como la mejor opción en pacientes electivos

AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients

High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic clopidogrel do not see a benefit in protection against periprocedural events and instead see increased costs and minor bleeding rate.&nbsp; These are the outcomes of the ALPHEUS study presented at AHA 2020 simultaneously published in the Lancet. Ticagrelor<a href="https://solaci.org/en/2020/11/20/aha-2020-clopidogrel-resists-as-the-best-option-in-elective-patients/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

In-Stent Restenosis Treatment: Meta-Analysis of 10 Randomized Studies

The best strategy to treat in stent restenosis continues to be a dilemma. A new drug eluting stent (DES) seems to be the simplest treatment, even though it adds metal layers that will make it harder and harder to retreat. Drug coated balloons might be a viable alternative seeing as it seems to enable retreatment,<a href="https://solaci.org/en/2020/11/18/in-stent-restenosis-treatment-meta-analysis-of-10-randomized-studies/" title="Read more" >...</a>

Nueva generación de stents farmacológicos

Dual Layered for Dual Protection in Carotid PCI

At present, there is more than one dual layered stent in the market offering additional protection in carotid PCI. Therefore we saw fit to look at these devices to compare class benefits and find any specific differences.&nbsp; This study assessed the safety and efficacy of two dual layered mesh covered stents especially designed for carotid<a href="https://solaci.org/en/2020/11/05/dual-layered-for-dual-protection-in-carotid-pci/" title="Read more" >...</a>

TCT 2020 | Our Next Goal Should Be Using IVUS Guidance in Every Angioplasty

The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3&nbsp;years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv. At 3&nbsp;years, target-vessel failure remained lower in patients whose angioplasty was guided by<a href="https://solaci.org/en/2020/10/22/tct-2020-our-next-goal-should-be-using-ivus-guidance-in-every-angioplasty/" title="Read more" >...</a>

TCT 2020 | Nueva información sobre el valor del FFR antes y después de la angioplastia

TCT 2020 | The Myth of Biodegradable Polymers Seems to Have Come to an End

This is the largest and newest study to compare drug eluting stents with durable polymers vs. biodegradable or bioresorbable polymers. As is usually the case, the theory clashes with reality.&nbsp; The study has shown that the polymer does not seem to play an important role in the performance of drug eluting stents, or at least<a href="https://solaci.org/en/2020/10/21/tct-2020-the-myth-of-biodegradable-polymers-seems-to-have-come-to-an-end/" title="Read more" >...</a>

TCT 2020 | Xience se suma a la evidencia de doble antiagregación corta en alto riesgo de sangrado

TCT 2020 | Xience in Favor of Short Dual Antiaggregation Therapy with High Bleeding Risk

Following with aspirin alone after a short period of dual antiaggregation therapy (DAPT), 1 to 3 months, did not increase ischemic events in patients receiving a Xience stent while significantly reducing bleeding.&nbsp; This study endorses the safety of short DAPT with contemporary drug eluting stents (DES) in patients presenting high bleeding risk.&nbsp; The XIENCE Short<a href="https://solaci.org/en/2020/10/21/tct-2020-xience-in-favor-of-short-dual-antiaggregation-therapy-with-high-bleeding-risk/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Diabetes Could Decide between Ticagrelor and Prasugrel

Diabetes has an impact on the relative effect of ticagrelor and prasugrel in patients undergoing acute coronary syndrome (ACS) according to a recent analysis of the ISAR-REACT 5 published in JACC Intv. Similarly to the main study outcomes, this sub-analysis of the ISAR-REACT 5 has shown that the combined end point of death, MI or<a href="https://solaci.org/en/2020/10/16/diabetes-could-decide-between-ticagrelor-and-prasugrel/" title="Read more" >...</a>

perforación coronaria en angioplastia

Complex PCI: Complex Characteristics Impact Results

Patients with a bigger number of complex anatomical characteristics that increase PCI complexity have worse results at one-year followup. These data come from a large multicenter study (e-Ultimaster) recently published in EuroIntervention. The more complex the characteristics, the greater the increase in events.&nbsp; It is important to see past the obvious anatomical challenges (bifurcations, calcification,<a href="https://solaci.org/en/2020/10/14/complex-pci-complex-characteristics-impact-results/" title="Read more" >...</a>

Post TAVR ASA Monotherapy Consolidates

This meta-analysis to be published in J Am Cardiol supports the use of aspirin monotherapy (ASA) after transcatheter aortic valve replacement (TAVR). The use of aspirin alone is associated to less bleeding without increased ischemic events such as strokes or mortality.&nbsp; The combined outcomes of four studies, including the recently published POPular TAVI (cohort A),<a href="https://solaci.org/en/2020/10/07/post-tavr-asa-monotherapy-consolidates/" title="Read more" >...</a>

Top